Just bought a little more in the IRA. Never though
Post# of 72440
So I guess I'll be a bit more rich when one of the drug trials has great results.
This is absurdly priced for a biotech with 4 clinical trials for 4 different indications. Look at AXON -- which I think is a Wall Street insiders playground -- 1.34 Billion with a B market cap, for a company that doesn't have ANY drugs in a clinical trial, and their intellectual property consists of one drug that they bought for 5 million because it failed and was shelved by a big pharma.
Efficient market theory, hah!